Effects of metformin, glyburide and their combination on lipid profile in NIDDM patients

Abstract

Background and Objectives: DM plays an important role in the endothelial dysfunction and vascular complications like dyslipidemia and atherosclerosis., It is important now a day to evaluate the dyslipidemic effects of oral hypoglycemic drugs in addition to blood glucose lowering effects, since this may provides a better treatment approach and participates in the prevention of complications of DM. Patients and Methods :We studied the dyslipidemic effects of glyburide, metformin, and their combination on (111) NIDDM patients aged from 39 – 58 years, treated for two years with different treatment lines and compared the results with healthy controls. Serum (TC-C), (TG-C),(HDL-C),(VLDL-C), and (LDL-C) levels were estimated as a marker of dyslipidemia in the serum utilizing lipid profile kit. Results: Serum TC-C, TG-C, LDL-C, and VLDL-C levels significantly reduced and serum HDL-C levels significantly elevated in patients used metformin alone and glyburide / metformin combination therapy so, maintained serum lipid profiles at levels closer to that of controls, while patients used glyburide as monotherapy significantly increased serum TG-C, TC-C, VLDL-C, and LDL-C levels and significantly decreased serum HDL-C levels in comparison to control group. Conclusion: Metformin / glyburide combination therapy and metformin monotherapy provide better protection against dyslipidemia associated with NIDDM patients than glyburide used alone, and hence better prevention of complications like atherosclerosis.